Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) Revenue (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Revenue for 16 consecutive years, with $30.6 million as the latest value for Q4 2025.

  • Quarterly Revenue changed 0.04% to $30.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $112.8 million through Dec 2025, down 5.91% year-over-year, with the annual reading at $112.8 million for FY2025, 5.91% down from the prior year.
  • Revenue for Q4 2025 was $30.6 million at Anika Therapeutics, up from $27.8 million in the prior quarter.
  • The five-year high for Revenue was $44.3 million in Q2 2023, with the low at -$2.9 million in Q4 2023.
  • Average Revenue over 5 years is $30.8 million, with a median of $32.5 million recorded in 2021.
  • The sharpest move saw Revenue tumbled 107.78% in 2022, then skyrocketed 1155.61% in 2024.
  • Over 5 years, Revenue stood at $35.8 million in 2021, then crashed by 107.78% to -$2.8 million in 2022, then fell by 4.02% to -$2.9 million in 2023, then surged by 1155.61% to $30.6 million in 2024, then rose by 0.04% to $30.6 million in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $30.6 million, $27.8 million, and $28.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.